The FDA assigned INO-3107 a Prescription Drug User Fee Act (PDUFA) review goal date of October 30, 2026, which is the date by which it intends to take action on the application. The FDA has indicated ...
This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...
It has been claimed that because most of our DNA is active, it must be important, but now human-plant hybrid cells have been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback